Key result
Combined immunosuppressive therapy with antithymocyte globulin, cyclosporine, and high-dose glucocorticoids led to the recovery of giant cell myocarditis and clinical remission in a 34-year-old male.
Case Report (n=1)
Antithymocyte globulin (ATG) combined with cyclosporine and high-dose glucocorticoids represents a potential treatment option for patients with acute giant cell myocarditis.
Answers are grounded in this paper and cite their sources.
May support ATG-based immunosuppression in acute giant cell myocarditis; hypothesis-generating and requires prospective trials before practice change.
We report on a challenging case of a 34-year-old male patient with giant cell myocarditis (GCM) and fulminant relapse after discontinuing immunomodulatory therapy 2 years after the initial event. Specific combined immunosuppressive therapy with antithymocyte globulin (ATG), cyclosporine and high-dose glucocorticoids combined with guideline-based heart failure medication led to the recovery of GCM, improvement of systolic left ventricular function and clinical remission. This case report emphasises the importance of an immunosuppressive therapy for the prognosis and outcome and the risk of discontinuation. Most importantly, ATG seems to be one new possible potential treatment option for patients with acute GCM.
No takes yet. Share an insight, caveat, or question.
Fluschnik et al. (2014) conducted a case report in Giant cell myocarditis (n=1). Combined immunosuppressive therapy with antithymocyte globulin (ATG), cyclosporine and high-dose glucocorticoids was evaluated on Recovery of GCM, improvement of systolic left ventricular function and clinical remission. Combined immunosuppressive therapy with antithymocyte globulin, cyclosporine, and high-dose glucocorticoids led to the recovery of giant cell myocarditis and clinical remission in a 34-year-old male.
Synapse has enriched 10 related papers. Consider them for comparative context: